EGFR and neoplasm: For instance, in lung adenocarcinoma (LUAD), TP53 mutations are prevalent in EGFR mutant tumors but are strongly underrepresented in KRAS-driven LUAD151,163, indicating different paths of tumor evolution driven by different oncogenes.